Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

被引：146
作者：
Booij, J
Tissingh, G
Winogrodzka, A
van Royen, EA
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Nucl Med, Grad Sch Neurosci Amsterdam, NL-1105 AZ Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Neurol, Grad Sch Neurosci Amsterdam, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1999年 / 26卷 / 02期
关键词：
single-photon emission tomography; positron emission tomography; parkinsonism; dopamine transporter imaging; dopamine D-2 receptor imaging;
D O I：
10.1007/s002590050374
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Parkinsonism is a feature of a number of neurodegenerative diseases, including Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. The results of post-mortem studies point to dysfunction of the dopaminergic neurotransmitter system in patients with parkinsonism. Nowadays, by using single-photon emission tomography (SPET) and positron emission tomography (PET) it is possible to visualise both the nigrostriatal dopaminergic neurons and the striatal dopamine D-2 receptors in vivo. Consequently, SPET and PET imaging of elements of the dopaminergic system can play an important role in the diagnosis of several parkinsonian syndromes. This review concentrates on findings of SPET and PET studies of the dopaminergic neurotransmitter system in various parkinsonian syndromes.
引用
收藏
页码：171 / 182
页数：12
相关论文
共 136 条
[1]  
Abi-Dargham A, 1996, J NUCL MED, V37, P1129
[2]  
ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119
[3]   [C-11] RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY IN PREVIOUSLY UNTREATED PATIENTS WITH PARKINSONS-DISEASE - INFLUENCE OF L-DOPA AND LISURIDE THERAPY ON STRIATAL DOPAMINE D-2-RECEPTORS [J].
ANTONINI, A ;
SCHWARZ, J ;
OERTEL, WH ;
BEER, HF ;
MADEJA, UD ;
LEENDERS, KL .
NEUROLOGY, 1994, 44 (07) :1325-1329
[4]   Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease [J].
Antonini, A ;
Leenders, KL ;
Vontobel, P ;
Maguire, RP ;
Missimer, J ;
Psylla, M ;
Günther, I .
BRAIN, 1997, 120 :2187-2195
[5]   INVIVO EVALUATION OF STRIATAL DOPAMINE REUPTAKE SITES USING C-11 NOMIFENSINE AND POSITRON EMISSION TOMOGRAPHY [J].
AQUILONIUS, SM ;
BERGSTROM, K ;
ECKERNAS, SA ;
HARTVIG, P ;
LEENDERS, KL ;
LUNDQUIST, H ;
ANTONI, G ;
GEE, A ;
RIMLAND, A ;
UHLIN, J ;
LANGSTROM, B .
ACTA NEUROLOGICA SCANDINAVICA, 1987, 76 (04) :283-287
[6]  
ARNETT CD, 1986, J NUCL MED, V27, P1878
[7]  
Asenbaum S, 1997, J NUCL MED, V38, P1
[8]  
ASENBAUM S, 1997, SPECT NEUROLOGY PSYC, P187
[9]   REGIONAL BRAIN UPTAKE AND PHARMACOKINETICS OF [I-123] N-OMEGA-FLUOROALKYL-2-BETA-CARBOXY-3-BETA-(4-IODOPHENYL)NORTROPANE ESTERS IN BABOONS [J].
BALDWIN, RM ;
ZEAPONCE, Y ;
ALTIKRITI, MS ;
ZOGHBI, SS ;
SEIBYL, JP ;
CHARNEY, DS ;
HOFFER, PB ;
WANG, SY ;
MILIUS, RA ;
NEUMEYER, JL ;
INNIS, RB .
NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (02) :211-219
[10]  
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
12345678910